stoxline Quote Chart Rank Option Currency Glossary
  
Longeveron Inc. (LGVN)
3.25  0.12 (3.83%)    03-28 16:00
Open: 3.64
High: 3.64
Volume: 147,435
  
Pre. Close: 3.13
Low: 3.2
Market Cap: 57(M)
Technical analysis
2024-03-28 4:52:40 PM
Short term     
Mid term     
Targets 6-month :  4.25 1-year :  4.96
Resists First :  3.64 Second :  4.25
Pivot price 0.8
Supports First :  1.59 Second :  0.33
MAs MA(5) :  1.49 MA(20) :  0.73
MA(100) :  1.19 MA(250) :  2.18
MACD MACD :  0.3 Signal :  0
%K %D K(14,3) :  59.9 D(3) :  38.3
RSI RSI(14): 92.6
52-week High :  4.4 Low :  0.33
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ LGVN ] has closed above the upper band by 15.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 622.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.64 - 3.66 3.66 - 3.67
Low: 3.17 - 3.18 3.18 - 3.2
Close: 3.23 - 3.25 3.25 - 3.27
Company Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Headline News

Wed, 27 Mar 2024
Longeveron Inc. (NASDAQ:LGVN) Sees Large Decline in Short Interest - MarketBeat

Tue, 26 Mar 2024
LGVN Stock Quote Price and Forecast - CNN

Mon, 25 Mar 2024
Longeveron (NASDAQ:LGVN shareholders incur further losses as stock declines 18% this week, taking one-year ... - Yahoo News Australia

Sat, 23 Mar 2024
Longeveron Stock Set to Reverse Split on Wednesday, March 27th (NASDAQ:LGVN) - Defense World

Thu, 21 Mar 2024
Longeveron (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split - The Globe and Mail

Thu, 07 Mar 2024
Earnings call: Longeveron reports progress in key clinical trials By Investing.com - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 10 (M)
Held by Insiders 7.29e+006 (%)
Held by Institutions 10.1 (%)
Shares Short 463 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.006e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -8 %
Return on Assets (ttm) 598.4 %
Return on Equity (ttm) -66.5 %
Qtrly Rev. Growth 709000 %
Gross Profit (p.s.) -154.52
Sales Per Share -507.07
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -19 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 3.73
Stock Dividends
Dividend 0
Forward Dividend 192940
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android